Gfb-887 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 222 | 一次性ネフローゼ症候群 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04387448 (ClinicalTrials.gov) | July 28, 2020 | 11/5/2020 | A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease | A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease | Kidney Diseases;Diabetic Nephropathies;Glomerulosclerosis, Focal Segmental;Nephrosis, Lipoid;Urologic Diseases;Diabetes Complications;Diabetes Mellitus;Endocrine System Diseases;Glomerulonephritis;Nephritis;Nephrosis | Drug: GFB-887;Drug: Placebo | Goldfinch Bio, Inc. | NULL | Recruiting | 18 Years | 75 Years | All | 125 | Phase 2 | United States |